Alliance Pharma Regulatory News (APH)

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

CULS Conversion and Additional Listing

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that pursuant to the Compulsory Conversion notice dated 7th November 2013 it will automatically convert the outstanding £3,525 nominal value of the Company's 8% Convertible Unsecured Loan Stock into Ordinary Share Capital. Accordingly, the Company has allotted 16,785 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), subject to admission of the Ordinary Shares to trading on AIM.

Application has been made by Alliance for the 16,785 Ordinary Shares to be admitted to trading on AIM, and it is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 31 December 2013.

Following conversion and allotment, Alliance will have 264,080,873 Ordinary Shares and no remaining 8% Convertible Unsecured Loan Stock in issue.

.

For further information:

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.